Viking Therapeutics, Inc. (VKTX)

Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

VKTX Advances Obesity Program With New Oral Maintenance Study

VKTX Down 16% in a Month: Time to Invest or Exit the Stock?

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

Here Are My Top 4 Stocks to Buy in October

LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies

Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?

Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors

Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy

Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

3 Non-AI Growth Stocks That Have Massive Upside

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm